Zonampanel (INN, code name YM872) is a quinoxalinedione derivative drug and competitive antagonist of the AMPA receptor which was being investigated by Yamanouchi/Astellas Pharma as a neuroprotective drug for the treatment of ischemic stroke but never completed clinical trials.[1][2][3][4] In clinical trials, zonampanel produced severe side effects including hallucinations, agitation, and catatonia in patients, resulting in early termination of the trials.[5]
 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H9N5O6 |
| Molar mass | 331.244 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
edit- ^ Jain KK (14 February 2011). The Handbook of Neuroprotection. Springer Science & Business Media. pp. 154–. ISBN 978-1-61779-049-2.
- ^ Ray A, Gulati K (1 January 2007). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
- ^ Waxman S (27 May 2005). Multiple Sclerosis As A Neuronal Disease. Academic Press. pp. 245–. ISBN 978-0-08-048941-4.
- ^ Gill S, Pulido O (31 January 2007). Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS. Springer Science & Business Media. pp. 37–. ISBN 978-0-306-48644-9.
- ^ Farooqui AA (2 September 2010). Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. Springer Science & Business Media. pp. 73–. ISBN 978-1-4419-6652-0.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |